Przuntek H - Search Results

1

Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice.

Kupsch A, Gerlach M, Pupeter SC, Sautter J, Dirr A, Arnold G, Opitz W, Przuntek H, Riederer P, Oertel WH. Kupsch A, et al. Among authors: przuntek h. Neuroreport. 1995 Mar 7;6(4):621-5. doi: 10.1097/00001756-199503000-00009. Neuroreport. 1995. PMID: 7605913

2

Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?

Russ H, Mihatsch W, Gerlach M, Riederer P, Przuntek H. Russ H, et al. Among authors: przuntek h. Neurosci Lett. 1991 Feb 11;123(1):115-8. doi: 10.1016/0304-3940(91)90171-o. Neurosci Lett. 1991. PMID: 1712088

3

Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations.

Mihatsch W, Russ H, Gerlach M, Riederer P, Przuntek H. Mihatsch W, et al. Among authors: przuntek h. J Neural Transm Park Dis Dement Sect. 1991;3(1):73-8. doi: 10.1007/BF02251138. J Neural Transm Park Dis Dement Sect. 1991. PMID: 1905937

4

Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice.

Gerlach M, Russ H, Winker J, Witzmann K, Traber J, Stasch JP, Riederer P, Przuntek H. Gerlach M, et al. Among authors: przuntek h. Arzneimittelforschung. 1993 Apr;43(4):413-5. Arzneimittelforschung. 1993. PMID: 7684224

5

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Gerlach M, Riederer P, Przuntek H, Youdim MB. Gerlach M, et al. Among authors: przuntek h. Eur J Pharmacol. 1991 Dec 12;208(4):273-86. doi: 10.1016/0922-4106(91)90073-q. Eur J Pharmacol. 1991. PMID: 1815982 Review.

6

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Blum-Degen D, et al. Among authors: przuntek h. Neurosci Lett. 1995 Dec 29;202(1-2):17-20. doi: 10.1016/0304-3940(95)12192-7. Neurosci Lett. 1995. PMID: 8787820

7

Pharmacokinetic studies with sustained-release formulations of levodopa in healthy volunteers.

Gerlach M, Gebhardt B, Kuhn W, Przuntek H. Gerlach M, et al. Among authors: przuntek h. J Neural Transm Suppl. 1988;27:211-8. doi: 10.1007/978-3-7091-8954-2_18. J Neural Transm Suppl. 1988. PMID: 3165436 Clinical Trial.

8

Diagnostic staging of Parkinson's disease: conceptual aspects.

Przuntek H, Müller T, Riederer P. Przuntek H, et al. J Neural Transm (Vienna). 2004 Feb;111(2):201-16. doi: 10.1007/s00702-003-0102-y. J Neural Transm (Vienna). 2004. PMID: 14767723 Review.

9

4,4-Diphenylpiperidine derivates and their sila analogues. A comparative study of their interaction with neural receptor biding sites and synaptosomal monoamine uptake.

Stasch JP, Russ H, Schacht U, Witteler M, Neuser D, Gerlach M, Leven M, Kuhn W, Jutzi P, Przuntek H. Stasch JP, et al. Among authors: przuntek h. Arzneimittelforschung. 1988 Aug;38(8):1075-8. Arzneimittelforschung. 1988. PMID: 2848535

10

Sustained-release of levodopa: single dose study of a new formulation.

Gerlach M, Kuhn W, Müller T, Klotz P, Przuntek H. Gerlach M, et al. Among authors: przuntek h. J Neural Transm (Vienna). 1996;103(6):717-27. doi: 10.1007/BF01271231. J Neural Transm (Vienna). 1996. PMID: 8836933 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters